(Q40204932)

18 September 2017

title

Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists (English)

1 reference

18 September 2017

author

Cornelis J. M. Melief

5

object named as

Cornelis J M Melief

1 reference

18 September 2017

Sjoerd H van der Burg

7

object named as

Sjoerd H van der Burg

1 reference

18 September 2017

4

Kees L M C Franken

1 reference

18 September 2017

Marij J P Welters

1

1 reference

18 September 2017

Martijn S Bijker

2

1 reference

18 September 2017

Susan J F van den Eeden

3

1 reference

18 September 2017

Rienk Offringa

6

1 reference

18 September 2017

language of work or name

English

0 references

publication date

7 November 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

25

1 reference

18 September 2017

issue

8

1 reference

18 September 2017

page(s)

1379-1389

1 reference

Dendritic cell immunotherapy: mapping the way.

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Dendritic cell-mediated T cell polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Controlling the Toll road to dendritic cell polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Activation of Dendritic Cells That Cross-Present Tumor-Derived Antigen Licenses CD8+ CTL to Cause Tumor Eradication

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

inferred from DOI database lookup

7 January 2021

based on heuristic

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Role of Toll-like receptors in costimulating cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Differential effects of corticosteroids during different stages of dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Interferons, Interferon Inducers, and Interferon-Ribavirin in Treatment of Flavivirus-Induced Encephalitis in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

In vivo and In vitro interferon induction in chickens by S -28828, an imidazoquinolinamine immunoenhancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Dynamic programming of CD8+ T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Enhanced Dendritic Cell Antigen Capture via Toll-Like Receptor-Induced Actin Remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Cutting edge: distinct roles for T help and CD40/CD40 ligand in regulating differentiation of proliferation-competent memory CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Sustained response initiation is required for T cell clonal expansion but not for effector or memory development in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Cutting edge: priming of CTL by transcutaneous peptide immunization with imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Ssytemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

Induction of lymphocyte recruitment in the absence of a detectable immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.10.049

10.1016/J.VACCINE.2006.10.049

7 January 2021

Identifiers

DOI

1 reference

18 September 2017

1 reference